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Abstract
The development of engineered skeletal muscle would provide a viable tissue for replacement and
repair of muscle damaged by disease or injury. Our current tissue-engineering methods result in
three-dimensional (3D) muscle constructs that generate tension but do not advance phenotypically
beyond neonatal characteristics. To develop to an adult phenotype, innervation and vascularization
of the construct must occur. In this study, 3D muscle constructs were implanted into the hindlimb
of a rat, along the sciatic nerve, with the sural nerve isolated, transected and sutured to the construct
to encourage innervation. Aortic ring anchors were sutured to the tendons of the biceps femoris
muscle so that the construct would move dynamically with the endogenous muscle. After 1week
in vivo, the constructs were explanted, evaluated for force production and stained for muscle, nerve
and collagen markers. Implanted muscle constructs showed a developing capillary system, an
epimysium-like outer layer of connective tissue and an increase in myoﬁbre content. The beginning
of a-bungarotoxin clustering suggests that neuromuscular junctions (NMJs) could form on the
implanted muscle, given more time in vivo. Additionally, the constructs increased maximum isomet-
ric force from 19241 mN to 549103 mN (245% increase) compared to in vitro controls, which in-
creased from 27623 mN to 32927mN (25% increase). These ﬁndings suggest that engineered
muscle tissue survives 1week of implantation and begins to develop the necessary interfaces needed
to advance the phenotype toward adult muscle. However, in terms of force production, the muscle
constructs need longer implantation times to fully develop an adult phenotype. Copyright © 2012
John Wiley & Sons, Ltd.
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1. Introduction
The development of engineered skeletal muscle would
provide a viable option for replacement and repair of
damaged skeletal muscle in humans as well as a viable
model for studying the effects of stressors and chemicals
on muscle (Khodabukus et al., 2007). The current method
for skeletal muscle repair, the muscle ﬂap, is hindered by
limited tissue availability and donor site morbidity. Our
laboratory has developed a reproducible method for the
development of scaffold-less engineered muscle con-
structs (Larkin et al., 2006). The engineered muscle we
fabricate consists of a 3D construct with a ﬁbroblast-
produced extracellular matrix (ECM) and myotubes
aligned along the axis of strain. This in vitro construct can
generate force either spontaneously or in response to elec-
trical ﬁeld stimulation. Engineered skeletal muscle is lim-
ited in vitro in that it does not develop beyond a neonatal
phenotype in terms of strength characteristics and tissue
organization (Larkin et al., 2006; Huang et al., 2010).
Two interfaces that we aimed to establish in our implanted
constructs are neural and vascular. Our laboratory has
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enhanced engineered muscle in vitro through the co-culture
of muscle and fetal nerve cells (Larkin et al., 2005). Other
work has been done to successfully enhance scaffolded
engineered muscle function by mimicking neural stimula-
tion through bioreactors that deliver cyclic electric pulses
(Donnelly et al., 2010). In order for engineered muscles to
grow to physiological sizes, a vascular network must be
established. Dennis and Kosnik (2000) showed that myo-
blasts are unable to differentiate and proliferate more than
150mm away from oxygen and nutrient supplies. Other
research groups have shown that the foreign body response
observed during in vivo implantation supports the ingrowth
of a capillary network into the implanted constructs (Beier
et al., 2006; Saxena et al., 2001).
In addition to the beneﬁts of neural and vascular inter-
faces, we expected our constructs to demonstrate a posi-
tive response to the cyclic mechanical stretching provided
by the movement of the host muscles. Mechanical stimu-
lation in vitro has been performed using bioreactors on
scaffolded muscle tissue (Gonen-Wadmany et al., 2004;
Powell et al., 2002) to enhance skeletal muscle phe-
notype. Gonen-Wadmany et al. (2004) showed that
mechanical stimulation improves cell-mediated collagen
compaction, resulting in improved cellular alignment.
Thus, we hypothesized that the implantation of our
muscle construct in an anatomical location to provide
mechanical stretch during ambulation of the animal
would enhance the phenotype when compared with the
maintained in vitro construct.
The purpose of this research was to investigate the
effect of 1week of in vivo implantation on scaffold-less
engineered skeletal muscle constructs with respect to
contractile properties, structure, vascularization and
innervation. We hypothesized that the 1week of implan-
tation of muscle constructs would shift the phenotype
from neonatal toward adult and that muscle constructs
would exhibit an increase in force production.
2. Materials and methods
2.1. Animal model and animal care
Tissue-engineering studies were carried out using muscle
tissue from female Fischer 344 rats, obtained from
Charles River Laboratories Inc. (Wilmington, MA, USA).
All animals were acclimated to our colony conditions,
i.e. light cycle and temperature, for 1week prior to any
procedure. The animals were fed Purina Rodent Chow
5001 laboratory chow and water ad libitum. Surgical pro-
cedures were performed to remove both soleus muscles
and aorta from a subset of the female Fisher rats. These
rats were obtained as retired breeders with an estimated
age of 8–9months. These harvested tissues were then
used as an allogenic cell source for muscle precursor cells
and anchoring tissues (aortic rings) for the constructs
fabricated and implanted into the host animals. All surgi-
cal procedures were performed in an aseptic environment,
with animals in a deep plane of anaesthesia induced by
intraperitoneal (i.p.) injections of sodium pentobarbital
(65mg/kg). Supplemental doses of pentobarbital were
administered as required to maintain an adequate depth
of anaesthesia. All animal care and animal surgery proce-
dures were in accordance with The Guide for Care and Use
of Laboratory Animals (National Research Council, 1996);
the experimental protocol was approved by the University
Committee for the Use and Care of Animals.
2.2. Preparation of media
Unless otherwise indicated, all solutions and media were
prepared and stored at 4C prior to isolation and culture
of cells and warmed to 37C in a heated water bath
immediately prior to use. Muscle growth medium
(MGM) contained 300ml F-12 Kaighn’s Modiﬁcation
Nutrient Mixture (Gibco BRL, cat. no. 21127–022),
125ml Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Gibco BRL, cat. no. 11995–065), 75ml fetal bovine serum
(FBS; Gibco BRL, cat. no. 10437–028), 2.4 ng/ml basic
ﬁbroblast growth factor (bFGF; Peprotech) and 5ml
antibiotic–antimycotic (ABAM; Gibco BRL, cat. no.
15240–062). Muscle differentiation medium (MDM)
was composed of 330mlM199 (Gibco BRL, cat. no.
11150–059), 140ml DMEM, 33ml FBS, 500 ml insulin
transferring selenite-X (ITS-X; 1/1000 dilution), 362ml
50mM ascorbic acid 2-phosphate (Sigma-Aldrich), and
5ml ABAM (Gibco BRL, cat. no. 15240–062). Transport
medium (TM) consisting of Dulbecco’s phosphate-buffered
saline (DPBS), pH 7.2 (Gibco BRL, cat. no. 14190–144), sup-
plemented with 2% ABAM, was used to transfer freshly
isolated tissues from the surgical suite to the tissue culture
facilities for isolation.
2.3. Preparation of construct dishes
Muscle constructs were engineered in individual 60mm
plates, as described previously (Larkin et al., 2006). Each
60mm plate was coated with 5ml Sylgard (Dow Chemical
Corp., Midland, MI, USA; type 184 silicon elastomer) and
allowed to cure for 3weeks prior to use; 1–7days prior to
use, Sylgard-coated plates were coated with laminin at
0–0.71 mg/cm2/plate [20 mg NaturalMouse Laminin (Gibco
BRL, cat. no. 23017–015) and 4ml Dulbecco’s phosphate-
buffered saline (DPBS), pH 7.2 (Gibco BRL, cat. no.
14190–144) per plate], and left to dry for 48h. Salt crystals
were dissolved and removed by rinsing the plates with 4ml
DPBS. The plates were then ﬁlled with 3ml previously
described MGM and decontaminated with UV light (wave-
length 253.7 nm) for 60min and placed in a 37C 5% CO2
incubator for up to 1week prior to plating the muscle cells.
2.4. Preparation of acellular aorta ring anchors
The descending aortas of Fischer 344 rats were surgically
removed under aseptic conditions. Cells were removed
from the aorta, leaving just the ECM, by immersing the
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tissue sequentially in one of ﬁve detergent solutions over a
period of 15 days, as outlined in Haase et al. (2003). The
compositions of the solutions were as follows: solution 1,
7.3 g ethylenediamine tetra-acetic acid (EDTA), 0.5 g
sodium azide (NaN3), 800ml glycerol, 200ml 0.9% NaCl;
solution 2, 25 g sodium deoxycholate; 0.26 g NaN3, 600ml
distilled and deionized water; solution 3, 10 g sodium
dodecylsulphate (SDS), 0.52 g NaN3 and 1000ml distilled
and deionized water; solution 4, 0.5 g NaN3, 1000ml 0.9%
saline; solution 5, 15ml Triton X-100, 0.25 g NaN3 and
485ml distilled water.
2.5. Dissection of muscle and isolation of
muscle cells
Both soleus muscles were surgically removed under
aseptic conditions, weighed and sterilized in 70% ETOH.
Prior to dissociation, muscles were incubated in TM (at
a concentration of 5ml/muscle dissected) for 5min. A
20ml dissociation solution consisting of 32 U dispase
(Sigma, cat. no. P-3417; 0.4 U/mg) and 2390 U type 4 col-
lagenase (Gibco BRL, cat. no. 17104–019), 239 U/mg)/ml
Ham’s F12 (Gibco BRL, cat. no. 11765–054) was utilized.
Two soleusmuscles were dissociated for each 20ml solution
for a minimum of a 1.5h time period. The dissociated cell
solution was poured through a 100mm ﬁlter, centrifuged
and aspirated prior to being resuspended in 15ml MGM
and preplated overnight in a 100mm tissue culture dish.
The supernatant from the preplate was removed and
brought to a density of 1.3  105 cells/ml; 3ml of the cell
suspension were plated in each of the previously prepared
laminin-coated culture dishes and placed in a 37C, 5%
CO2 incubator. The culture plates were not disturbed for
at least 72h to allow cell adherence to the plates.
2.6. Preparation of muscle constructs
Muscle constructs were fabricated as previously described
(Larkin et al., 2006) with the exception that aortic rings
were used as anchors instead of adult rat tail tendon.
Brieﬂy, 5 days after initial plating, the cells were fed with
MGM every 48 h until the cells became conﬂuent (approx-
imately 7 days). Once the cells achieved conﬂuence, they
were fed with MDM every 48 h until the myocytes fused
to form multinucleated myotubes that began to contract
spontaneously. At this time point, the aortic rings were
pinned as anchors with minutien pins onto the muscle
monolayer at a separation distance of 15mm. The aortic
rings acted as anchors and enabled the muscle monolayer
to roll up into a 3D cylinder. Approximately 7 days later, a
cylindrical 3D muscle construct was formed in each dish.
The cells were fed MDM every 48 h during the co-culture
of the muscle constructs. Five days after construct forma-
tion, the muscle constructs were tested for contractile
function as described in Section 2.8 below. At the conclu-
sion of functional tests, each specimen was snap-frozen
in Tissue Freezing Media (Triangle Biological Sciences,
Durham, NC, USA) in isopentane chilled with dry ice,
and stored at 80C for subsequent histology.
2.7. Implantation of muscle constructs
F344 retired breeder rats were anaesthetized using iso-
ﬂourane; the analgesic, Carprofen (5mg/kg) was admin-
istered following induction of anaesthesia and every
12 h for 48 h post-surgery. The left leg vastus lateralis
and biceps femoris muscles were separated, exposing the
sciatic nerve. Approximately 10mm of sural nerve was
separated from the peroneal and tibial nerves and from
the surrounding connective tissue. A small surface blood
vessel from the medial edge of the biceps was dissected,
exposing a 10mm section, with the proximal end open.
Muscle constructs were surgically placed in the hindlimb
alongside the femur. The transected ends of the sural
nerve and blood vessel were placed next to the muscle
belly and sutured to the construct to encourage innerva-
tion and vascularization of the construct. The aortic rings
of the constructs were sutured with 9–0 suture silk to the
proximal and distal tendons of the biceps femoris muscle,
so that they would experience mechanical stresses and
move dynamically with the endogenous muscle. The vas-
tus lateralis and biceps femoris muscles were sutured
together, using 7–0 suture (Ethicon), and the skin incision
was closed using 9mm autoclips (Becton-Dickinson). The
animals were allowed to recover for 7 days. At the end of
the 7 day implantation, the muscle constructs were dis-
sected, placed in MDM and their contractile properties
were measured.
2.8. Contractile property testing
Contractile properties were measured prior to (day 0) and
7days after implantation of the muscle constructs. The
protocol for measuring contractility of engineered muscle
constructs was adapted from Dennis and colleagues
(Dennis and Kosnik, 2000; Dennis et al., 2001; Kosnik
et al., 2001) and Irintchev et al. (1998). Brieﬂy, the pin
on one end of the construct was freed from the Sylgard
and attached to a force transducer with canning wax.
For ﬁeld stimulation of the entire construct, platinum wire
electrodes were positioned on either side of the construct.
The temperature of the construct was maintained at 37 
1 C, using a heated aluminium platform. The diameter
of the construct was determined and used to calculate
cross-sectional area, assuming a circular cross-section.
Passive baseline force was measured as the average base-
line passive force preceding the onset of stimulation.
Twitches were elicited using a single 2.5ms pulse at 10,
30, 60 and 90mA, whereas maximum tetanic force was
determined using a 1 s train of 2.5ms pulses at 90mA
and 10, 20, 40, 60 and 80Hz. Data ﬁles for each peak
twitch force and peak tetanic force trace were recorded
and subsequently analysed, using LabVIEW data acquisi-
tion software. Peak tetanic force was normalized for
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cross-sectional area to determine maximum speciﬁc force.
Following the direct ﬁeld stimulation of the entire con-
struct, a micro-electrode was used to electrically stimulate
the neural extensions projecting from the explanted
constructs, using the same stimulation parameters as
described above for the ﬁeld stimulation.
2.9. Histochemical and immunohistochemical
analysis of 3D muscle constructs
Unﬁxed muscle constructs were placed into TBS medium
(Triangle Biological Sciences, Durham, NC, USA), frozen
in cold isopentane and stored at 80C until needed.
Samples were sliced in the muscle portion of the con-
struct to obtain cross-sections with a cryostat at a thick-
ness of approximately 12mm, adhered to Superfrost Plus
microscopy slides and used for staining. Sections were
stained for general morphology observations with hae-
matoxylin and eosin (H&E), as previously described
(Luna, 1968). For immunohistochemical analysis, frozen
sections were ﬁxed with ice-cold methanol for 10min
and rinsed with phosphate-buffered saline (PBS). Sec-
tions were blocked for 30min with PBS–0.05% Tween20
(PBST) containing 20% calf serum (PBST-S) at room
temperature. The sections were incubated overnight at
4C with the primary antibodies diluted in PBST-S.
Immunoﬂuorescent staining with speciﬁc antibodies
was performed to detect the presence of myosin heavy
chains (MCH; MF-20 mouse monoclonal antibody 1:5
dilution, obtained from the Developmental Studies
Hybridoma Bank, Iowa City, IA, USA), a-actinin (mouse
monoclonal antibody; 1:200 dilution; Sigma, St. Louis,
MO, USA), nebulin (mouse monoclonal antibody,
1:100 dilution; Abcam, Cambridge, MA, USA), PAX7
(rabbit polyclonal antibody, 1:100 dilution; Abcam), col-
lagen type 1 (rabbit polyclonal antibody, 5 mg/ml;
Chemicon International, Temecula, CA, USA), blood
vessels (rabbit polyclonal anti-CD31 antibody, 10 mg/ml;
Abbiotec, San Diego, CA, USA), nerve ﬁbres (rabbit
polyclonal anti-S-100 antibody, 1:100 dilution; Abcam)
and mouse monoclonal anti-pan-axonal neuroﬁlament
marker SMI312 antibody (1:500; Covance, Emeryville,
CA, USA). Following three washes in PBST, a 1 h room
temperature incubation with Cy3-conjugated anti-mouse
or anti-rabbit antibody (Jackson ImmunoResearch Lab-
oratory, West Grove, PA) was used for visualization.
Following three washes in PBST, nuclei were stained by
5min incubation with DAPI solution (Sigma) in PBST.
According to previously described methods (Kostrominova,
2011), staining of sections with ﬂuorescein-labelled wheat
germ agglutinin (WGA, 5mg/ml for 5min; Molecular
Probes, Eugene, OR, USA) was used for visualization of
connective tissue. For visualization of developing neuromus-
cular junctions, muscle sections were incubated for 10min
at room temperature in the solution of a-bungarotoxin
(a-BTX–rhodamine, 1mg/ml; Sigma). The sections were
examined and photographed with a Leica microscope and
cross-sections of the constructs were analysed using a
software package, Image J.
2.10. Statistics
Values are presented as mean SE. Statistical analysis was
performed using Staveiw (SAS Institute Inc., Cary, NC,
USA). A one-way analysis of variance (ANOVA) was con-
ducted to compare the differences between muscle con-
structs implanted in vivo for 1week and in vitro constructs.
Differences were considered signiﬁcant at p< 0.05.
Figure 1. Cross-section of an in vitromuscle construct stained with H&E (A, B) and for myosin heavy chains (red), collagen I (green)
and nuclei (DAPI, blue) (C, D)
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3. Results
3.1. Morphology of muscle constructs
H&E staining of the engineered muscle constructs was
performed in order to compare general morphology of
in vitro constructs (Figure 1A, B) with 1week implanted
muscle constructs (Figure 2A, B). Immunostaining was
used to visualize sarcomeric myosin heavy chains (red)
and collagen type I (green) in the in vitro (Figure 1C, D)
compared to implanted (Figure 2C, D) constructs. Cell
nuclei were visualized with DAPI (blue). Collagen 1
immunostaining showed a distinct epimysium-like outer
layer of collagen formed at the periphery of the explanted
constructs (arrows in Figure 2C, D). Additional muscle
marker staining for a-actinin and nebulin show striations
due to developed sarcomeres (Figure 2F, H) and staining
for PAX7 showed differentiating multinucleated myosin
(Figure 2G). Sarcomeric myosin was present at the higher
level in the 1week implanted compared to in vitro control
constructs. Analysis of cross-sections of the constructs
using a software package, Image J, showed 20.2% by area
more myoﬁbre staining in the implanted constructs than
in in vitro controls (66.5 2.1% of the total area vs
45.3 4.9%, respectively).
Figure 2. Cross-section of an explanted muscle construct stained with H&E (A, B) and for myosin heavy chains (red), collagen I (green)
and nuclei (DAPI, blue) (C, D). Immunostaining of the longitudinal sections of muscle construct after implantation in vivowith antibodies
against MHC (E), a-actinin (F), PAX7 (G) and nebulin (H). Nuclei were stained with DAPI (blue in E–H). Small arrows in (F, H) indicate
striations due to the presence of the developed sarcomeres. Small arrowheads in (G) indicate perinuclear staining of the non-differentiated
myoblasts. Large arrowheads in (G) indicate nuclear staining of the myoblasts in the process of differentiation and fusion
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Longitudinal sections of the implanted muscle con-
structs stained with antibodies against CD31 indicated
that after just 1week, there was vascularization of the
constructs (Figure 3A, B). Immunostaining with anti-
haemoglobin antibody to demonstrate vessel functionality
could not be performed, due to the developing muscle
being stained as well, probably due to the cross-reaction
with myoglobin (data not shown). However, the CD31
staining provides good evidence of a developing vascula-
ture in 1week explants. Staining with antibodies against
NCAM showed nerve ﬁbres in the sural nerve located in
the proximity to the muscle constructs (small arrowheads
in Figure 4A, B). Therewas noNCAM-positive immunostain-
ing in the muscle constructs. Staining with a-bungarotoxin
for acetylcholine receptors showed intensive staining of
the plasma membrane of the developing muscle ﬁbres
(arrows in Figure 4A, C, D). In a few areas clustering of
the acetylcholine receptorswas observed (large arrowheads
in Figure 4A, D), suggesting an initiation of neuromuscular
junction formation. Immunostaining with antibodies
against pan-axonal neuroﬁlament marker showed the pres-
ence of nerve ﬁbres in the sural nerve, located in the prox-
imity to themuscle construct (arrow in Figure 4E).Wewere
able to detect nerve ﬁbre sprouting in one section of one
muscle construct (arrows in Figure 4F), suggesting out-
growth of axonal processes from the sural nerve into the
muscle construct. However, functional testing suggested
that 1week implanted muscle constructs did not have
well-formed neuromuscular junctions capable of transmit-
ting action potentials to the muscle. Aortic rings proved an
acceptable anchor for the constructs as the aorta–muscle
interface stayed intact during all testing (data not shown).
3.2. Contractile properties
The muscle constructs exhibited spontaneous baseline
activity and could elicit both a twitch and a tetanus
response to ﬁeld stimulation. Following 1week of implan-
tation, the explanted muscle constructs increased in size,
on average from 63073mm to 732105 mm, while the
in vitro constructs shrank, but not signiﬁcantly, changing
on average from 462 29 mm to 42753 mm (Figure 5A).
The implanted constructs increased maximum isometric
force from 192 mN to 549 mN (245% increase) compared
to in vitro controls that increased from 276 mN to 329
mN (25% increase) over the same time period (Figure 5B,
C). The change in isometric force generated between the
two groups was signiﬁcant (p> 0.05). Following the ﬁeld
stimulation of the muscle construct, microelectrodes were
used to electrically stimulate the neural extensions radia-
ting from the construct. In all nine implanted constructs,
there was no response to direct stimulation of the regener-
ating nerve extension, indicating a lack of functional
innervation (data not shown).
4. Discussion
The purpose of this research was to investigate the effect
of a 1week in vivo implantation on advancement of
phenotype in scaffold-less engineered skeletal muscle
constructs. We hypothesized that 1week of implantation
with mechanical stimulation and surgical supplementa-
tion of nerve and vasculature would shift the phenotype
of the engineered muscle from neonatal toward adult
and that muscle constructs would exhibit an increase in
force production.
Following 1week of exposure to the in vivo environ-
ment, including mechanical stresses, the muscle constructs
increased isometric force production. Previous studies from
our laboratory showed that when muscle constructs were
exposed to 1week of innervation with the tendon ends of
the construct sutured to the belly of a muscle, it resulted
in necrosis of the muscle tissue (data not shown). Although
a blood vessel was not routed to the constructs in this pilot
study, the constructs were quickly encapsulated in a ﬁbrotic
sheath and vascularized. This suggests that the introduction
of the blood vessel and/or the mechanical stresses placed
on the construct by anchoring it to the tendons of the biceps
femoris drove the construct to develop a more adult phe-
notype. This increase in adult phenotype was concluded
from the data measuring a 20.2% increase in the myosin
staining in the muscle tissue. In addition to the increase in
myosin staining, we observed that the cross-sections of
the implanted construct were larger. Assessment of the
Figure 3. Longitudinal section of an explanted muscle construct
stained for blood vessels (CD31, red), connective tissue (WGA,
green) and nuclei (DAPI, blue) (A, B)
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construct in longitudinal sections indicated an increase in
the longitudinal alignment of muscle ﬁbres along the axis
of the muscle from end to end.
The beneﬁcial effect of neurotization on muscle tissue
development has been studied extensively (Baltich et al.,
2010; Das et al., 2010). The appearance of small acetyl-
choline receptor clusters in our explants in the proximity
to the junction of endogenous nerve and engineered mus-
cle tissue suggests that the muscle tissue responds to the
regenerating nerve signalling by clustering of acetylcho-
line receptors. In a similar study performed on scaffolded
muscle by Dhawan et al. (2007), scaffolded constructs
were implanted with or without nerve transection to
promote neurotization of the constructs. In that study,
the explanted neurotized constructs generated a force of
649 mN, while explanted non-neurotized constructs gen-
erated only 124 mN. Theseﬁndings support our hypothesis
that neurotization will play a large role in increasing the
maximum isometric force of our constructs, as compared
to in vitro controls, given more time in vivo. As stated
above, unpublished pilot studies from our laboratory, in
which nerve but not vasculature was supplied to the
regenerating muscle in vivo, suggest that immediate
vascularization may initially play a bigger role in tissue
survival than innervation; 2 and 4week implants have
been proposed as a future research goal for our laboratory
to improve the level of neurotization and vascularization
of the constructs.
Mechanical stimulation has been determined to play an
important role in the development of skeletal muscle
in vitro. Candiani et al. (2010) showed that 10 days on a
bioreactor resulted in an eight-fold increase in myosin
accumulation in stretched constructs as compared to
static controls. Comparatively, Figures 1C and 2C show
an increase in staining for myosin heavy chain in
implanted constructs as compared to in vitro controls. In
support of this data was an increase in force production.
Future studies from our laboratory will look at the contri-
bution of mechanical stress on the development of a more
advanced phenotype, by placing a subset of engineered
muscle constructs on bioreactors prior to implantation.
The timing for muscle development must be weighed with
the decreased diffusion of substrate into larger more
developed muscle constructs in vitro and increased risk
Figure 4. Longitudinal section of an explanted muscle construct stained with antibodies against S100 to visualize nerve ﬁbres (green; A,
B),a-bungarotoxin to visualize acetylcholine receptors (red; A, C, D) andwith antibodies against axonal neuroﬁlamentmarker (red; E, F).
Nuclei were stained with DAPI (blue; A–F). Connective tissue in (E, F) was stained with WGA lectin (green). Small arrowheads in (A, B)
indicate nerve ﬁbres in the sural nerve placed in the proximity of the muscle construct. Arrows in (A, C) indicate developingmuscle ﬁbres
with a-bungarotoxin-stained plasma membrane. Large arrowheads in (A, D) indicate small clusters of acetylcholine receptors at the
developing muscle ﬁbres. Arrows in (E, F) indicate nerve ﬁbres in sural nerve and muscle construct, respectively
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of cell death in the central area of the constructs, due to
the lack of nutrients and oxygen.
In conclusion, 1week of an in vivo environment
resulted in constructs with multinucleated muscle
ﬁbres and a-actinin-stained sarcomeres, as well as
greater force-producing capabilities. This advancement
of muscle phenotype seen after implantation brings
us closer to our goal of using engineered muscle con-
structs for tissue repair. Future studies in our labora-
tory will continue to examine the development of the
neural and vascular interfaces with our engineered
muscle constructs and the viability of replacing whole
muscles with engineered tissue.
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